Posted on

Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements

Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements

Los Angeles JOLLA, Calif. , Aug. 31, 2020 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company centered on the development and development of revolutionary medicines focusing on microRNAs, today announced that pursuant to an amendment of its term loan contract with Oxford LLC, the organization is eligible for up to one more seven months of great interest just re re payments if your Company pays down ten dollars million in loan principal before April 30, 2021 (the “Principal Paydown Event”) utilizing arises from the purchase of materials to, and prospective milestones received from, Sanofi as described below. Continue reading Regulus Therapeutics Announces Restructuring of Sanofi and Oxford Loan Agreements